

## **Supplemental information on US FDA approval for Diclofenac Sodium Tablets.**

The company has yesterday issued a press release on receipt of US FDA approval to its ANDA for Diclofenac Sodium Tablets (25mg. & 50mg.).

The company already markets 75 mg. tablets of Diclofenac Sodium in US market. It was also stated in the said press release that the estimated market in US for Diclofenac Sodium formulations is US \$ 400 million.

This approval will boost the company's business prospects for Diclofenac Sodium formulations in US market as the company now has full range of Diclofenac Sodium tablets. Accordingly, the company estimates its sales of these formulations in US market at about US \$ 10 million by FY 2011-12.

### **About JBCPL:**

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMFs and ANDAs. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at [www.jbcpl.com](http://www.jbcpl.com). For more details, you may contact:

M.C. Mehta  
Company Secretary- General Manager  
J. B. Chemicals & Pharmaceuticals Ltd.  
91 22 3045 1311

-- x --

*Forward Looking Statements:*

*This supplemental Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.*